secwatch.observer — SEC 8-K summary
======================================

Issuer:     GYRE THERAPEUTICS, INC. (GYRE)
CIK:        0001124105
Form:       8-K
Filed at:   2026-01-05T23:59:59+00:00
Accession:  0001140361-26-000253
Event type: regulatory
Sentiment:  positive
Materiality: 0.75
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Gyre Therapeutics aligns with China's CDE on Hydronidone conditional approval pathway after Pre-NDA meeting
--------------------------------------------------------------------------------

- CDE agreed existing Phase 3 data for Hydronidone supports conditional approval NDA for CHB-associated liver fibrosis.
- CDE indicated Hydronidone meets priority review criteria; NDA submission planned for H1 2026.
- Company will conduct a confirmatory Phase 3c trial to support conversion from conditional to regular approval.
- Previously reported Phase 3 met primary endpoint: 52.85% treated vs 29.84% placebo achieved ≥1-stage fibrosis regression (p=0.0002).

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126000253/0001140361-26-000253-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1124105/000114036126000253/ny20062326x1_8k.htm
  HTML page:      https://secwatch.observer/filing/0001140361-26-000253

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer